drugset / Trial / NCT03242967

Study to Evaluate Three Times Per Week (TIW) Oral Dosing of Vadadustat for Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD)

NCT03242967

Phase 3 Withdrawn Akebia Therapeutics
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a Phase 3 Study to Evaluate Three Times Per Week (TIW) Oral Dosing of Vadadustat for Anemia in Subjects with Dialysis-Dependent Chronic Kidney Disease (DD-CKD)

Timeline

Start
2017-08
Primary completion
2018-02-12
Completion
2018-02-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Darbepoetin alfa Protein / enzyme biologic Subcutaneous
Subject Vadadustat Small molecule Oral